ClinicalTrials.gg
RecruitingNCT06084572WinProUpdated Mar 19, 2025

Prospective Evaluation of PH-impedance Tracings According to the Wingate Consensus, and Influence on GERD Classification According to the Lyon Consensus

An observational study in GERD, sponsored by Universitair Ziekenhuis Brussel. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-19.

Sponsored by Universitair Ziekenhuis Brussel · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
120
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 54 studies in Gastroesophageal Reflux with a site in Belgium — 2 open to participants now, 3 under way, none of them phase 3. Gastroesophageal Reflux · Belgium.

Started
2023
with 2 others
Observational
8 of 54
1 open now
Registered
54th of 54
by date
Lead sponsor
3 of 54
Universitair Ziekenhuis Brussel

Among the 54 studies in Gastroesophageal Reflux with a site in Belgium, this one is one of 3 that started in 2023, is one of 8 observational ones, and was the 54th registered.

Gastroesophageal Reflux

1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

2 of the 54 studies in Gastroesophageal Reflux with a site in Belgium are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Gastroesophageal Reflux with a site in Belgium, or all of them as a file.
02

Study summary

Commonly, in clinical practice an automated analysis of pH-MII tracings is obtained.

Read the detailed description

All pH-MII performed in UZ Brussel are already reviewed manually according to the Wingate con-sensus and interpreted according to the Lyon consensus. In this study, we will prospectively categorise the reasons for discarding reflux episodes identified by automated analysis during the manual review according to the Wingate consensus, as well as the impact on different parameters related to the interpretation of pH-MII. Based on comments received to our retrospective study, we will evaluate possible confounders to the interpretation, including the indication for referral for pH-MII, symptom severity, use of PPI during pH-MII.

03

Conditions studied

  • GERD

Keywords

  • GERD
  • pH-impedance
  • Wingate-consensus
  • Lyon consensus
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients referred for pH-MII are eligible.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged 18 - 80 years old;
  • pH-MII performed off PPI

Exclusion criteria

Exclusion Criteria:

  • Prior upper GI endoscopy indicative of structural disease (except for oesophagitis or hiatal hernia).
  • Incomplete pH-MII (less than 21 hours recording);
  • Ph-MII performed on PPI
  • Suboptimal quality of the tracings preventing interpretation in clinical practice;
  • Prior oesophageal (including anti-reflux intervention) or gastric surgery.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Groups and cohorts

  • GERD patients

    Other: Questionnaires

Interventions

  • OtherQuestionnaires

    FSSG \& BEDQ

06

What researchers measure

Primary outcomes

  1. Statistical difference in the GERD categorisation

    the statistical difference in the distribution of GERD categorisation between automated vs. manual review of the pH-MII tracings

    Time frame: During baseline visit

Secondary outcomes

  1. The analysis of the influence of different parameters on application of the Wingate criteria: including the Indication for referral with further classification into predominant oesophageal and extra-oesophageal symptoms;

    Time frame: During baseline visit

  2. The analysis of the influence of different parameters on application of the Wingate criteria: including the GERD Symptom Severity;

    Time frame: During baseline visit

  3. The analysis of the influence of different parameters on application of the Wingate criteria: including the patient being on or off PPI;

    Time frame: During baseline visit

  4. The analysis of the influence of different parameters on application of the Wingate criteria: including MNBI (obtained by automated analysis or manually calculated);

    Time frame: During baseline visit

  5. Presence of significant correlations between censored episodes and pH-MII parameters

    Correlations including: * Acid exposure time; * Total number of reflux episodes identified by impedance monitoring; * MNBI; * PSPWI.

    Time frame: During baseline visit

  6. Impact of the Wingate criteria on The number of PSPW;

    Time frame: During baseline visit

  7. Impact of the Wingate criteria on The number of symptoms associated with an impedance episode.

    Time frame: During baseline visit

  8. Impact of the Wingate criteria on the number of impedance episodes with or without acidic reflux

    Time frame: During baseline visit

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Apr 2026, 30 months after the start.

Of 95 non-industry observational studies under Gastroesophageal Reflux, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 167. This study's planned 30 months is below that.

Counting every sponsor, half of 117 studies reached it within 45 months; a quarter within 17 and three quarters within 134.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2023
First posted
Oct 16, 2023
StartActual
Sep 29, 2023
Primary completionEst.
Apr 1, 2026
CompletionEst.
Apr 1, 2026
Last update
Mar 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06084572
Responsible party
Sponsor
First posted
Oct 16, 2023
Start date
Sep 29, 2023
Primary completion
Apr 1, 2026 (estimated)
Completion
Apr 1, 2026 (estimated)
Last update
Mar 19, 2025

Study contacts

Sébastien Kindt, Prof. Dr.
Contact
sebastien.kindt@uzbrussel.be
+32 2 477 ext. 60 11
Virgini Van Buggenhout
Contact
virgini.vanbuggenhout@uzbrussel.be
+32 2 477 ext. 60 11

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion